Trial reportArchives of dermatological research2025
Efficacy of topical tacrolimus 0.03% ointment in combination with microneedling versus topical phenytoin 2% cream in combination with microneedling for the treatment of non-segmental facial vitiligo.
Trial report in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innate immune activation in vitiligo: mechanisms and pathophysiological implications.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim of the studyTo evaluate the efficacy and safety of microneedling combined with tacrolimus 0.03% ointment versus microneedling combined with phenytoin 2% cream in the treatment of non-segmental facial vitiligo. MATERIALS AND
methodsThis was a prospective single-blinded randomized clinical trial conducted on a total of 40 patients with non-segmental facial vitiligo, who were distributed into two groups (each of 20 patients); group I (n = 20) were treated with microneedling combined with tacrolimus 0.03% ointment and group II (n = 20) treated with microneedling combined with phenytoin 2% cream. The approach was conducted for another time every 14 days for all cases for over a period of 6 months, then the cases were followed up for three months following the termination of the treatment sessions.
resultsThere were no statistically significant differences recorded between both groups in regard to all demographic data and disease characteristics (P > 0.05). As regards to clinical improvement, microneedling combined with tacrolimus 0.03% ointment was associated with a superior improvement compared to microneedling combined with phenytoin 2% cream, nevertheless, this improvement was not statistically significant. Also, microneedling combined with tacrolimus was associated with a higher patient satisfaction compared to microneedling combined with phenytoin 2% cream, however, this improvement was not associated with statistical significance.
conclusionOur results provide additional evidence for the potential positive role of phenytoin as a therapeutic option in patients with non segmental vitiligo. However, tacrolimus 0.03% ointment combined with microneedling was associated with a better response than phenytoin 2% cream combined with microneedling.
Indexed as
Identifiers
40185951What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.